The biogenic amines, serotonin (5HT), dopamine (DA) and norepinephrine (NE) were investigated for ability to produce central nervous stimulation in mice as measured by convulsions elicited by handling following intracerebral injection. Dose-response data indicated that both NE and 5HT produce CNS stimulation. The slopes of the first derivatives for 5 HT and DA are not similarto NE (-2.74) and are -20.8 and -1.0. The differences in slopes would suggest different receptor sites for the production of hyperactivity in mice. The findings of this investigation suggest that both serotonin and NE can induce central excitation. However, this excitation is not necessarily mediated through a common receptor site. Our experiments at least provide the framework for further exploration of possible differential brain receptor responsiveness for these two biogenic amines.
SchildkrautJ. J.Neuropharmacology of the affective disorders, Annual Review of Pharmacology13, 427–129, 1973.
2.
AxelrodJ.Noradrenaline: fate and control of its biosynthesis, Science173, 598–606, 1971.
3.
BloomF. E. and GiarmanJ. J.Physiologic and pharmacologic consideration of biogenic amines in the nervous system, Annual Review of Pharmacology8, 229–258, 1968.
4.
SulserF. and Sanders-BushE. Effect of drugs on amines in the CNS. Annual Review of Pharmacology 11, 209–230, 1971.
5.
DavisJ. M. and FannW. E.Lithium, Annual Review of Pharmacology11, 285–3031971.
6.
SchildkrautJ. J.In Lithium: Its Role in Psychiatric Research and Treatment, (edited by GershowS. and ShopsinB.), Plenum Press New York, 1974.
7.
KlermanG. L. and ColeJ. O.Clinical pharmacology of imipramine and related antidepressant compounds, Pharmacological Reviews17, 101–1411965.
8.
Brodie, B. B., Pages127–146 in The Scientific Basis of Drug Therapy in Psychiatry. Pctgfrmon Press, Oxford, 1965.
9.
PletscherA. Pages 649–654 in Psychopharmacology Review of Progress, 1957-1967 (Editor-in-chief, EkronD. H.), U. S. Govt. Printing Office, Washington, 1968.
10.
Storm-OlsenR. and Weil-MalherbeH. Humoral changes in manic-depressive psychosis with particular reference to the excretion of catecholamines in urine. Journal of Mental Science 14, 696–704, 1958.
11.
ShinfukuW.MichioO. and MasaoK.Catecholamine excretion in manic-depressive psychosis, Yonago Acta Medica 5, 109-114, 1961.
12.
SloaneR. B., HughesW. and HaustH.L., Catecholamine excretion in manic-depressive and schizophrenic psychosis and its relationship to symptomatology, Canadian Psychiatric Association11,6–19, 1966.
13.
GreenspanK.SchildkrautJ. J.GordonE. K.LevyB. and DurellJ. Catecholamine metabolism in affective disorders. Archives of General Psychiatry 21, 710–716, 1969.
14.
BunneyW. E.Jr., MurphyD.L., GoodwinF.K. and BorgeG.FThe switch process from depression to mania: relationship to drugs which alter brain amines, Lancet1, 1022–1027, 1970.
15.
SchildkrautJ. J.GordonE. K. and DurrrellJ. Catecholamine metabolism in affective disorders: 1. Normethanephrine and VMA excretion in depressed patients treated with Imipramine, Journal of Psychiatric Research3, 213–228, 1965.
16.
SchildkrautJ. J.KlermanG. L.HammondR. and FriendD. G. Excretion of 3-methoxy-4-hydroxymandelic acid (VMA) in depressed patients treated with antidepressant drugs, Journal of Psychiatric Research 2, 257-266, 1964.
17.
GlowinskiJ.AxelrodJ. and versenI.L.L., Regional studies of catecholamines in the rat brain. IV. Effects of drugs on the disposition and metabolism of H'-norepinephrine and H'-dopamine. Journal of Pharmacology and Experimental Therapeutics 153, 30–41, 1966.
18.
SchildkrautJ. J.DodgeG. A. and LogueM. A. Effects of tricyclic antidepressants on the uptake and metabolism of intracisternally administered norepinephrine-H2 in rat brain. Journal of Psychiatric Research 7, 29–34, 1969.
19.
PrangeA. J.McCurdyR. L.and Cochrane, C. M., The systolic blood pressure response of depressed patients to infused norepinephrine, Journal of Psychiatric Research5, 1–13, 1967.
20.
PareC. M. B. and SandlerMclinicalAand biochemical study of a trial of iproniazid in the treatment of depression, Journal of Neurology. Neurosurgery and Psychiatry22, 247–251, 1959.
21.
CoppenA.ShawD.M. and FarrelJ. P.Potentiation of the antidepressive effect of monoamine oxidase inhibitor by tryptophan, Lancet179, 1963.
22.
Van PraagH.M. and Korf, J., 1971.
23.
CoppenA. The biochemistry of affective disorders. British Journal of Psychiatry 113, 1237–1264, 1967.
24.
LapinT. P. and OxenkrugG. F.Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect, Lancet1, 132–136, 1969.
25.
GlassmanA. Indoleamines and affective disorders. Psychosomatic Medicine31, 107–114, 1969.
26.
ShawD. M.CampsF. E. and EcclestonE. C.S-hydroxytryptamine in the hind brain of depressive suicides, British Journal of Psychiatry1131407, 1967.
27.
BourneH. R.BunneyW. E. ColburnR. W.DavisJ. M.DavisJ. N.ShawD. M. and CoppenA. J.Noradrenaline, 5-hydroxytryptomine and 5-hydroxyindoleacetic acid in hind brains of suicide patients, Lancet2805, 1968.
28.
Pare, C M. B., YeunsD. P. H., Price, K. and StaceyR.S., S-hydroxytryptamine, noradrenaline and dopamine in brainstem, hypothalamus and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning, Lancet 2,133, 1969.
29.
DewckerS. J.MalmM.and Roos, B. E. Acie monoamino metabolites of cerebrospinal fluid in mental depression and mania, Journal of Neurochemistry13, 1545–1548, 1966.
30.
Roos, B. E. and SjostromR., 5-hydroxyindoleacetic acid levels in the cerebrospinal fluid after probenecid application in patients with manic-depressive psychosis, Pharmacol. Clin.1, 153–155, 1969.
31.
Van PraagH.M., KorfJ., DolsL. C W. and SchutT., A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as antidepressant. Psychopharmacologia, Berlin25, 14–21, 1972.
32.
CoppenA.WhybrowP. C. and NogueraR.The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potatiation by liothyranine, Archives of American Psychiatry26, 234–241, 1972.
33.
CoppenA.PrangeA. J.Jr., WhybrowP. C and NogueraR., Abnormalities of indoleamines in affective disorders, Archives of General Psychiatry26, 474–478, 1972.
34.
CoppenA.ShawO. M.and Herzberg, B., Tryptophan in the treatment of depression, Lancet 2,1178-1180, 1967.
35.
CocherneM.L-tryptophan versus ECT, Lancet11392, 1970.
36.
BroadhurstA. D.L-tryptophan versus ECT, Lancet I, 1393, 1970.
37.
CarrollF. J.MowbrayR. M.and Davies, B., Sequential comparison of L-tryptophan with ECT in severe depression, Lancet1, 967–969, 1970.
38.
Pare, C. M. B., Potentiation of monoamine oxidase inhibitor by tryptophan, Lancet2527, 1963.
39.
GlassmanA. H. and PlatmanS. R.Potentiation of a monoamine oxidase inhibitor by tryptophan, Journal of Psychiatric Research7, 63–65, 1970.
40.
OmuraY.Patho-physiology of acupuncture treatment: effects of acupuncture on cardiovascular and nervous systems, Acupuncture & Electro-Therapeut. Res. Int. J.1, 51–142, 1975.
41.
OmuraY.Patho-physiology of acupuncture effects, ACTH and morphine-like substances, pain, phantom sensations (phantom pain, itch and coldness), brain micro-circulation, and memory, Acupuncture & Electro-Therapeut. Res. Int. J. 2, 1-31, 1976.
42.
OmuraY.Pain threshold measurement before and after acupuncture: controversial results of radiant heat method and electrical method, and the roles of ACTH-like substances and endorphins, Acupuncture & Electro-Therapeut. Res., Int. J.3, 1–21, 1977.
43.
OmuraY.Editorial: Acupuncture (with possible roles of serotonin and melatonin) and related unorthodox methods of diagnosis and treatment: non-invasive sphenopalatine ganglionic block, abrasion of nasopharyngeal mucosa and applied kinesiology, Acupuncture & Electro-Therapeut. Res. Int. J.4, 69–89, 1979.
44.
BrodieB. and ReidW. D. Serotonin in brain: functional considerations. Advances in Pharmacology6, (B) 97, 1968.
45.
DewhurstW. G.New theory of cerebral amine function and its clinical applications, Nature. London2181130, 1968.
46.
Grahame-SmithD. G.Studies in viro on the relationship between brain tryptophan, brain 5HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan, Journal Neurochemistry18, 1053–1066, 1971.
47.
PerssonT. and RoosB. E5-hydroxytryptophan for depression, Lancet2987, 1967.
48.
HaleyT. J. and McCormickW. G.Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse, British Journal of Pharmacology12, 12–15, 1957.
49.
GoldsteinA.ArnovowL. and KaimanS. M.Principles of drug action: the basis of pharmacology, 2nd edn. Harper & Row, New York, 1973.
50.
Grahame-SmithD. G. and GreenA. R.The role of brain dopamine in the hyperactivity syndrome produced in rats after L-tryptophan and a monoamine oxidase inhibitor, British Journal of Pharmacology 50,442, 1974.
51.
NgK. Y.ChaseT. N. ColburnR. W. and KopinI. J.Dopamine: stimulation-induced from central neurons, Science172,487–489, 1971.
52.
BlumK.WallaceJ. E.CalhounW.TaborR. G. and EubanksJ. E.Ethanol narcosjs in mice. Serotonergic involvement, Experientia30, 1053–1054, 1974.
53.
ModighK.Studies on DL-5-hydroxytryptophan-induced hyperactivity in mice, Advances in Biochemistry and Psychopharmacology10213, 1974.
54.
DunnerD. L. and GoodwinF. K.Effect of L-tryptophan of brain serotonin metabolism in depressed patients, Archives of General Psychiatry26, 364–366, 1972.
55.
FawcettJ.MassJ. W. and HaroutuneD.Depression and MHPG excretion: response to dextroamphetamine and tricyclic antidepressants, Archives of General Psychiatry26, 246–251, 1972.
56.
Brodieet al,1966.
57.
Fuxe et at., 1971.
58.
Trendelenburg, 1961.
59.
BeerB. and LenardL.Pharmacology biochemistry and behavior. The effects of 6-hydroxydopamine in avoidance behavior, Submitted for Publication.
60.
MurphyD. L.DonnellyC. and MoskowitzJ.Catecholamine receptor function in depressed patients, American Journal of Psychiatry131, 1389–1391, 1974.
